Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Addict Biol. 2017 Nov 27;24(1):132–144. doi: 10.1111/adb.12578

Table 1.

Description of samples aggregated to identifying genetic factor related to alcohol dependence

Study N Description
Study of Addiction: Genetics and Environment (SAGE) 4,316 A multi-ethnic sample of unrelated individuals from three large, complementary data sets designed to study drug addiction: the Collaborative Study on the Genetics of Alcoholism (COGA), the Family Study of Cocaine Dependence (FSCD) and the Collaborative Genetic Study of Nicotine Dependence (COGEND).
Alcohol Dependence GWAS in European- and African Americans (Yale Study) 2,909 A case-control study focusing on AAs and EAs who meet DSM-IV criteria for AD. The sample was collected over the course of ongoing projects that focused on oversampling of alcohol dependent AAs and also included measures on cocaine and opioid dependence. The sample was originally collected to identify sibling pairs suitable for linkage analysis.
Australian twin-family study of alcohol use disorder (OZ-ALC) 6,701 A family study deriving from two general population volunteer cohorts of twins in Australia totaling over 11,000 families. Two cohorts of twins born between 1940–1961 (cohort 1) or 1964–1971 (cohort 2) were assessed using a shared protocol to discover genes related to alcohol use. Data from these studies were compiled into a case-control family-based GWAS that focused on alcohol use and dependence
Genome-Wide Association Study of Heroin Dependence (Heroin GWAS) 6,410 A collaboration of investigators from the United States and Australia to identify genes associated with heroin dependence using a case-control study. Data on participants from the Heroin Study who were assessed for dependence on alcohol consisted of the following from ongoing genetic studies of substance dependence conducted by investigators at Yale and collaborating institutions:
  1. Cases (i.e. individuals who reported participation in pharmacotherapy maintenance treatment for opioid dependence at some point in their life) and assessed controls (i.e. individuals not dependent on heroin) from the The Comorbidity and Trauma Study;

  2. Cases (i.e. individuals dependent on heroin) from the Heroin Dependence in Western Australia;

  3. Controls (i.e. individuals who were did not meet criteria for illicit drug dependence, but may have been dependent on alcohol or nicotine) from the OZ-ALC Study;

  4. Assessed controls (i.e. individuals who did not meet criteria for substance use dependence) and cases (i.e. individuals dependent on opioids with heroin listed as the most used opioid).